Drugmakers are racing to secure health records and strike deals with technology companies, all to discover how medicines perform in the real world.
Efficiently translating genomic research into the clinic is one of the most important steps in the development of the field. The clinic is where we will see things come to fruition.
AstraZeneca has made the decision to push six early-stage experimental drugs into a new $250 million standalone biotech company focused on severe autoimmune diseases.
GenomeAsia 100k are trying to close the genetic gap that exists in the South Asian population, by seeking to sequence 100 genomes from the region.
“How Can We Anticipate and Respond to Technologies and Information That is Rapidly Changing?” – Josephine Johnston
Josephine Johnston is an expert on the ethical, legal and policy implications of biomedical technologies, particularly as used in human reproduction, psychiatry, genetics, and neuroscience.
Scientists at the UNC School of Medicine and NC State have created an injectable gel-like scaffold that can hold combination chemo-immunotherapeutic drugs and deliver them locally to tumours in a sequential manner.
Stephen Kingsmore and his team at Rady Children’s recently proved they could sequence a whole genome in a world record time of 19.5 hours.
Clinicians can be so focused on fixing problems and saving lives that they often avoid delivering news of a poor prognosis.